| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2017-09-04 | DAV131 | Clostridium difficile infection | preclinical | Da Volterra (France) | Infectious diseases |
| 2017-08-31 | mirogabalin (DS-5565) | diabetic peripheral neuropathic pain - postherpetic neuralgia | 3 | Daiichi Sankyo (Japan) | CNS diseases - Neurological diseases |
| 2017-08-30 | MP0250 | solid tumors | 1 | Molecular Partners (Switzerland) | Cancer - Oncology |
| 2017-08-30 | MP0250 and osimertinib (Tagrisso®) | 1b/2 | Molecular Partners (Switzerland) | Cancer - Oncology | |
| 2017-08-29 | PBD-C06 | Alzheimer's disease | preclinical | Probiodrug (Germany) | Neurodegenerative diseases |
| 2017-08-29 | DS-8201 | HER2-positive unresectable and/or metastatic breast cancer resistant or refractory to ado-trastuzumab emtansine (T-DM1) | 2 | Daiichi Sankyo (Japan) | Cancer - Oncology |
| 2017-08-28 | imeglimin | type 2 diabetes | preclinical | Poxel (France) | Metabolic diseases |
| 2017-08-28 | inclisiran (ALN-PCSsc) | atherosclerotic cardiovascular disease, familial hypercholesterolemia | 2 | Alnylam Therapeutics (USA - MA) The Medicines Company (USA - NJ) | Cardiovascular diseases - Genetic diseases |
| 2017-08-28 | nivolumab and DS-8201 | HER2-expressing metastatic breast cancer, HER2-expressing metastatic urothelial cancer | 1b | BMS (USA - NY) Daiichi Sankyo (Japan) | Cancer - Oncology |
| 2017-08-24 | daratumumab in combination with bortezomib, melphalan and prednisone | front line multiple myeloma | 3 | Janssen Biotech - J&J (USA) Genmab (Denmark) | Cancer - Oncology |
| 2017-08-24 | AAV2/8-hCARp.hCNGB3 - adenovirus associated viral vector serotype 8 containing the human CNGB3 gene | achromatopsia due to mutations in the CNGB3 gene | 1-2 | MeiraGTx (USA - NY) | Rare diseases - Genetic diseases - Ophtalmological diseases |
| 2017-08-24 | AAV2/5-hRKp.RPGR | X-Linked retinitis pigmentosa (XLRP) | 1-2 | MeiraGTx (USA - NY) | Rare diseases - Genetic diseases - Ophtalmological diseases |
| 2017-08-24 | BI 1467335 (formerly known as PXS-4728A) | NASH (non-alcoholic steatohepatitis) | 2a | Boehringer Ingelheim (Germany) Pharmaxis (Australia) | Liver diseases - Hepatic diseases |
| 2017-08-22 | antibodies against alpha-synuclein and TDP-43 | neurodegenerative diseases | preclinical | AC Immune (Switzerland) | Neurodegenerative diseases |
| 2017-08-22 | PAT-1251 | idiopathic pulmonary fibrosis (IPF), fibrotic diseases | 1 | PharmAkea (USA - CA) | Lung diseases - Respiratory diseases - Rare diseases - Fibrotic diseases |
| 2017-08-21 | KAF156 in combination with lumefantrine | malaria | 2b | Novartis (Switzerland) | Parasitic diseases |
| 2017-08-21 | TAK-935/OV935 | developmental and/or epileptic encephalopathies, including Dravet Syndrome, Lennox-Gastaut Syndrome and Tuberous Sclerosis Complex | 1b/2a | Ovid Therapeutics (USA - NY) | Neurological diseases - CNS diseases - Neurodevelopmental diseases |
| 2017-08-21 | gilteritinib | acute myeloid leukemia with FLT3 internal tandem duplication (ITD) mutation-positive (FLT3/ITD+) | 3 | Astellas Pharma (Japan) | Cancer - Oncology |
| 2017-08-17 | KITE-718 (MAGE A3/A6 -Autologous genetically modified MAGE-A3/A6 TCR transduced T cells) | solid tumors | 1 | Kite Pharma (USA - CA) | Cancer - Oncology |
| 2017-08-16 | MIV-711 | osteoarthritis | 2 | Medivir (Sweden) | Rheumatic diseases - Inflammatory diseases – Bone diseases |
